

FOR IMMEDIATE RELEASE

Media Contact:

Deborah Spak, (224) 948-2349
media@baxter.com

Investor Contact:

Clare Trachtman, (224) 948-3085

Joele Frank, Wilkinson Brimmer Katcher

Matthew Sherman / Kelly Sullivan / Becky McClain
(212) 355-4449

BAXTER COMMENTS ON SCHEDULE 13D FILING BY THIRD POINT

DEERFIELD, Ill. – August 5, 2015 – Baxter International Inc. (NYSE: BAX) today issued the following statement in response to the Schedule 13D filed by Third Point LLC:

Baxter maintains open communication with its shareholders and values constructive input toward enhancing value. Baxter has engaged in various discussions with representatives of Third Point and expects to continue a constructive dialogue.

Baxter's Board and management team are committed to enhancing value for all Baxter shareholders. Baxter has a proven track record of taking action to create significant value and will continue to evaluate shareholder input, assess opportunities and make decisions to further achieve this important objective.

Baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices;

parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. The company's global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter's employees worldwide are building upon the company's rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.

This release includes forward-looking statements concerning Baxter's future actions. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: continued strength in the company's financial position, including cash flows; future decisions of the board of directors of the company; the ability to achieve the intended results from the recent separation of the biopharmaceutical and medical products businesses on the terms currently contemplated, if at all; and other risks identified in Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.

###